Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT

Share this content:
Approximately 60% to 90% of patients undergoing high-dose melphalan and ASCT develop neutropenic fever and infections.
Approximately 60% to 90% of patients undergoing high-dose melphalan and ASCT develop neutropenic fever and infections.

Prophylactic treatment with doxycycline plus ciprofloxacin reduces the incidence of neutropenic fever (NF) and infections among patients with multiple myeloma (MM) who underwent autologous stem cell transplant (ASCT) compared with fluoroquinolone alone, according to a study published in Supportive Care in Cancer.

Approximately 60% to 90% of patients undergoing high-dose melphalan and ASCT — the standard therapy for multiple myeloma — develop neutropenic fever and infections, a major cause of morbidity and mortality for this patient population; effective prophylactic therapy is of key importance.


For this retrospective review, investigators analyzed the health outcomes of 419 patients with multiple myeloma who underwent ASCT between 2004 and 2016; 301 patients received ciprofloxacin 500 mg plus doxycycline 100 mg (cipro-doxy arm), both agents twice daily, and 118 patients received ciprofloxacin 500 mg twice daily alone (cipro arm). Median age at time of ASCT was 58 years in the cipro only arm and 60 years in the cipro-doxy arm.

Results showed that 63 (53%) patients in the cipro arm developed NF vs 108 (36%) patients in the cipro-doxy arm (P =.010). Thirteen (11%) and 14 (4.7%) patients developed bacteremic episodes in the cipro arm and cipro-doxy arm, respectively.


Transplant-related mortality was 1% in both study arms, and Clostridium difficile infections and antimicrobial resistance did not occur frequently.

The authors concluded that “If findings are confirmed, the routine antimicrobial prophylaxis strategy for these patients may need to be changed.”

Reference

Sivik JM, Davidson J, Hale CM, Drabick JJ, Talamo G. Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma [published online March 21, 2018]. Support Care Cancer. doi: 10.1007/s00520-018-4165-6

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs